To investigate the associations of endogenous testosterone with prostate growing disorders (PGD) including benign prostatic hyperplasia (BPH) and prostate cancer (PCA).
The study population was composed by 1176 cases including 371 BPH subjects (31. 5%) without cancer who underwent prostate transurethral resection from January 2017 to November 2019 and 805 patients (68.5%) with PCA who underwent surgery from November 2014 to December 2019. The association of endogenous testosterone, which was measured before surgery, with the risk of PGD was evaluated by statistical methods.
In the study population, endogenous testosterone levels were significantly lower in PCA cases compared to BPH patients who were older with larger prostates but lower prostate-specific antigen (PSA) levels. On multivariate analysis, the risk of PCA decreased by endogenous testosterone (odds ratio, OR = 0.957; 95% CI 0.930-0.984; p = 0.002) as by age (OR = 0.955; 95% CI 0.933-0.984; p < 0,0001) and prostate volume (OR = 0.930; 95% CI 0.919-0.940; p < 0.0001) but increased by PSA (OR = 1.652; 95% CI 1.542-1.769; p < 0.0001). On multivariate linear regression analysis, endogenous testosterone inversely associated with body mass index (BMI) (regression coefficient, b = - 0.279; p = 0.002) and PCA (b = - 2.935; p < 0.0001).
In the aging male, endogenous testosterone independently predicted malignant prostate disorders, which associated with decreased hormone levels along BMI categories. Endogenous testosterone is a further marker for evaluating prostate growing disorders in clinical practice; however, controlled studies are required.
International urology and nephrology. 2021 Jan 03 [Epub ahead of print]
Antonio Benito Porcaro, Nelia Amigoni, Alessandro Tafuri, Riccardo Rizzetto, Aliasger Shakir, Leone Tiso, Clara Cerrato, Vincenzo Lacola, Stefano Zecchini Antoniolli, Alessandra Gozzo, Katia Odorizzi, Matteo Brunelli, Filippo Migliorini, Walter Artibani, Maria Angela Cerruto, Salvatore Siracusano, Alessandro Antonelli
Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Aristide Stefani 1, 37126, Verona, Italy. ., Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Aristide Stefani 1, 37126, Verona, Italy., Institute of Urology and Catherine and Joseph Aresty Department of Urology, USC, University of Southern California (USC), Keck School of Medicine, Los Angeles, CA, USA., Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.